Ongoing Clinical Trials - Renal and Urology News

RSS | Login | Register

Ongoing Clinical Trials

July 15, 2008

Print
Email
Reprint
Font Size: A | A | A

KIDNEY/URETERAL STONES

Randomized Control Trial Comparing Dual Probe Ultrasonic Lithotripsy to a Single Probe Ultrasonic Lithotripsy

Sponsor

Indiana Kidney Stone Institute

Contact

Shelly E. Handa, RN

Phone: 317-962-0870

E-mail: shanda@clarian.org

Principal Investigator

James E. Lingeman, MD

ClinicalTrials.gov Identifier

NCT00351351

Use of Symbiotics to Reduce Urinary Oxalate Excretion

Phase I/II

Sponsor

Mayo Clinic

National Institutes of Health

Contact

Beth B. Bjornson

Phone: 507-255-7768

E-mail: Bjornson.beth@mayo.edu

Principal Investigator

John C. Lieske, MD

ClinicalTrials.gov Identifier

NCT00587041

Effect of Cola on Urinary Stone Risk Factors

Sponsor

Emory University

Contact

Kenneth Ogan, MD (Principal Investigator)

Phone: 404-778-3038

E-mail: Kenneth_ogan

@emoryhealthcare.org

ClinicalTrials.gov Identifier

NCT00289120

The Efficacy of Tamsulosin in the Treatment of Ureteral Stones in Emergency Department Patients

Sponsor

William Beaumont Hospitals

Contact

Patrick B. Medado, BS

Phone: 248-898-0124

E-mail: pmedado

@beaumonthospitals.com

ClinicalTrials.gov Identifier

NCT00448123

Cystone for Treatment of Nephrolithiasis

Sponsors and collaborators

Mayo Clinic

Himalaya Herbal Healthcare

Contact

Ellen R. Olson

Phone: 507-255-3984

E-mail: olson.ellen@mayo.edu

Principal Investigator

Stephen B. Erickson, MD

ClinicalTrials.gov Identifier

NCT00381849

BLADDER CANCER

A Phase II Randomized Trial for Patients With Muscle-Invading Bladder Cancer Comparing Transurethral Surgery and BID Irradiation Plus Either Taxol and Cisplatin or 5-Fluorouracil and Cisplatin Followed by Selective Bladder Preservation and Gemcitabine/Paclitaxel/Cisplatin Adjuvant Chemotherapy

Sponsors and collaborators

Radiation Therapy Oncology Group

National Cancer Institute

Contact

R. Jeffrey Lee, MD

LDS Hospital

Salt Lake City, Utah

Phone: 801-408-1146

ClinicalTrials.gov Identifier

NCT00055601

A Phase II Study of Erlotinib (Tarceva®) in Patients With Muscle-Invasive Bladder

Cancer Undergoing Radical Cystectomy

Sponsors and collaborators

University of North Carolina

Chapel Hill Lineberger

Comprehensive Cancer Center

National Cancer Institute

Contact

Lineberger Comprehensive

Cancer Center

Clinical Trials Office

Phone: 919-966-4432

ClinicalTrials.gov Identifier

NCT00380029

PROSTATE CANCER

Community Interventions in Non-Medical Settings to Increase Informed Decision Making for Prostate Cancer Screening - Univ of Texas - SIP 21-04

Sponsors and collaborators

Centers for Disease Control

and Prevention

University of Texas

Health Science Center

Contact

Jessica A. Calderon, MPH

Phone: 915-747-8579

E-mail: Jessica.A.Calderon

@uth.tmc.edu

Evelyn Chan, MD, MS

Phone: 713-500-6705

E-mail: Evelyn.C.Chan

@uth.tmc.edu

ClinicalTrials.gov Identifier

NCT00137618

Phase Ib/II Evaluation of RAD001 With Docetaxel and Bevacizumab

in Patients With Metastatic Androgen Independent Prostate Cancer

Sponsors and collaborators

Cedars-Sinai Medical Center

Novartis

Genentech

Contact

Koo Nguyen, BS

Phone: 310-423-7600

E-mail: koo.nguyen@cshs.org

Tina Tolbert, BA

Phone: 310-423-7600

E-mail: tina.tolbert@cshs.org

ClinicalTrials.gov Identifier

NCT00574769

Active Surveillance in Prostate Cancer: A Prospective Cohort Study

Sponsor

M.D. Anderson Cancer Center

Contact

Jeri Kim, MD

(Principal Investigator)

Phone: 713-792-2830

ClinicalTrials.gov Identifier

NCT00490763

The Impact of Androgen Ablation Therapy on Cognitive Functioning and Functional Status in Men With Prostate Cancer Age 65 and Older

Sponsors and collaborators

Memorial Sloan-Kettering

Cancer Center

City of Hope

National Medical Center

Fordham University

Contact

Christian Nelson, PhD

E-mail: nelsonc@mskcc.org

ClinicalTrials.gov Identifier

NCT00579072

Detection of Prostate Cancer With Contrast-Enhanced Ultrasound After Treatment With Dutasteride

Sponsors and collaborators

Kimmel Cancer Center

National Cancer Institute

Contact

Clinical Trials Office

Kimmel Cancer Center

Phone: 215-955-6084

Principal Investigator

Ethan J. Halpern, MD

ClinicalTrials.gov Identifier

NCT00398281

RENAL CELL CARCINOMA

Phase II Safety and Efficacy Study of Capecitabine, Gemcitabine, and Bevacizumab

in Combination for Patients With Metastatic or Unresectable Sarcomatoid Renal Cell Carcinoma

Sponsors and collaborators

M.D. Anderson Cancer Center

Eli Lilly and Company

Contact

Lance Pagliaro, MD

(Principal Investigator)

Phone: 713-792-2830

ClinicalTrials.gov Identifier

NCT00496587

Multicenter Phase II Study of Non-Myeloablative Allogeneic Stem Cell Transplantation Using Matched Unrelated Donor for Metastatic Renal Cell Carcinoma

Sponsors and collaborators

Center for International Blood

and Marrow Transplant Research

M.D. Anderson Cancer Center

Contact

Rebecca Drexler

Phone: 612-884-8654

E-mail: rdrexler@nmdp.org

ClinicalTrials.gov Identifier

NCT00318110

Phase II Study of Low Dose Decitabine (5-Aza-Deoxycytidine) With Interferon Alfa-2b in Advanced Renal Cell Carcinoma

Sponsors and collaborators

M.D. Anderson Cancer Center

MGI Pharma, Inc.

Contact

Ana M. Aparicio, MD (Principal Investigator)

Phone: 713-792-2830

ClinicalTrials.gov Identifier

NCT00561912

Phase II, Single Arm Trial of Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-Risk Patients With Metastatic Renal Cell Carcinoma

Sponsors and collaborators

Massachusetts General Hospital

Pfizer

Beth Israel Deaconess Medical Center

Dana-Farber Cancer Institute

Contact

Beverly Spicer, RN

Phone: 617-726-8235

E-mail: bspicer@partners.org

ClinicalTrials.gov Identifier

NCT00556049

HEMODIALYSIS

Short-Term Study of Physiologic Dialysate Dextrose Concentration in Chronic Hemodialysis Patients

Sponsor

Renal Research Institute

Contact

Sudhi Tyagi

Phone: 646-672-4058

E-mail: styagi@rriny.com

Mary Carter

Phone: 212-360-4934

E-mail: mcarter@rriny.com

ClinicalTrials.gov Identifier

NCT00618033

Frequent Hemodialysis Network: Nocturnal Trial

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Contact

Paul W. Eggers, PhD

Phone: 301-594-8305

E-mail: eggersp@extra.niddk.nih.gov

Andrew S. Narva, MD

Phone: 301-594-7717

E-mail: narvaa@niddk.nih.gov

ClinicalTrials.gov Identifier

NCT00271999

Study of Clinical Outcomes of More Frequent Hemodialysis

Sponsor

Satellite Healthcare

Contact

Brigitte Schiller-Moran, MD

Phone: 650-404-3640

E-mail: schillerb@satellitehealth.com

Sheila J. Doss, RN, CCRA

Phone: 650-404-3621

E-mail: dosss@satellitehealth.com

ClinicalTrials.gov Identifier

NCT00575497

Comparison of Daily Nocturnal Hemodialysis With Daily Hemodialysis

Sponsor

National Center for Research Resources

Contact

Brent W. Miller, MD (Principal Investigator)

Phone: 314-286-0801

ClinicalTrials.gov Identifier

NCT00012441

Pilot/Feasibility Randomized Control Trial to Examine the Effect of Oral Nutritional Supplements With Anti-Inflammatory/Anti-Oxidative Properties and Pentoxiphylline on Malnutrition-Inflammation-Cachexia Syndrome in Maintenance Hemodialysis Patients

Sponsors and collaborators

National Institute of Diabetes and Digestive and Kidney Diseases

DaVita, Inc.

Abbott Nutrition

Sanofi-Aventis

Contact

Kamyar Kalantar-Zadeh, MD, MPH, PhD

Phone: 310-222-2346

E-mail: kkalantar@ucla.edu

Arezu Dezfuli, MD

Phone: 310-222-2346

E-mail: adezfuli@labiomed.org